Implementation of the genome-informed risk assessment (GIRA) may lead to large disruptions to the health system
This study evaluating the Genome-Informed Risk Assessment (GIRA) in the Penn Medicine Biobank reveals that while the tool effectively identifies a large proportion of high-risk patients across diverse ancestries, its implementation at scale poses significant challenges due to disparities in risk stratification by ancestry and socioeconomic status, as well as a notable gap between its ability to predict prevalent versus incident disease cases.